SlidesetHIVViral Hepatitis and Liver DiseaseInternational Workshop on HIV & Hepatitis Co-infection 2017Management of end-stage liver disease in HIV patients- Ana Morbey, MDView Slideset
JRJürgen RockstrohMDSlidesetHIVViral Hepatitis and Liver DiseaseInternational Workshop on HIV & Hepatitis Co-infection 2017EASL highlights 2017- Jürgen Rockstroh, MDView Slideset
RSeCRui Sarmento e CastroMD, PhD, MPHSlidesetHIVViral Hepatitis and Liver DiseaseInternational Workshop on HIV & Hepatitis Co-infection 2017Management of HCV in intravenous drug users: special considerations- Rui Sarmento e Castro, MD, PhDView Slideset
VSVincent SorianoMD, PhDSlidesetHIVViral Hepatitis and Liver DiseaseInternational Workshop on HIV & Hepatitis Co-infection 2017News on hepatitis delta and HIV infections- Vincent Soriano, MD, PhDView Slideset
KSKenneth ShermanMD, PhDSlidesetHIVViral Hepatitis and Liver DiseaseInternational Workshop on HIV & Hepatitis Co-infection 2017Hepatitis E in HIV- Kenneth Sherman, MD, PhDView Slideset
SlidesetViral Hepatitis and Liver DiseaseInternational Workshop on HBV Cure 2018Innate activation with Inactivated parapox viruses for HBV therapy - AIC649 | Daniela PaulsenView Slideset
SlidesetViral Hepatitis and Liver DiseaseInternational Workshop on HBV Cure 2018Combination treatment of a TLR7 agonist RO7020531 and a core protein allosteric modulator RO7049389 achieved sustainable viral load suppression and HBsAg loss in an AAV-HBV mouse model | Yonghong ZhuView Slideset
MMMala MainiMD, PhDSlidesetViral Hepatitis and Liver DiseaseInternational Workshop on HBV Cure 2018Rationale for modulating innate immunity: TLR, RIG- and others | Mala Maini, MD, PhDView Slideset
SlidesetViral Hepatitis and Liver DiseaseInternational Workshop on HBV Cure 2018Antiviral effect of the RIG-I agonist, Inarigavir | Nezam AfdahlView Slideset
JFJordan FeldMD, MPHSlidesetViral Hepatitis and Liver DiseaseInternational Workshop on HBV Cure 2018What are the pros and cons of HBsAg loss as the endpoint for treatment? | Jordan Feld, MD, MPHView Slideset
AGAdam GehringPhDSlidesetViral Hepatitis and Liver DiseaseInternational Workshop on HBV Cure 2018Will HBsAg depletion restore HBV specific immunity? | Adam Gehring, PhDView Slideset
TBThomas BergMDSlidesetViral Hepatitis and Liver DiseaseInternational Workshop on HBV Cure 2018Stopping Nucleos(t)ide Analogues: When is it beneficial, when is it dangerous? | Thomas Berg, MDView Slideset
